JBIO NASDAQ
Jade Biosciences, Inc.
1W: +4.8%
1M: +0.6%
3M: -26.4%
YTD: +2.4%
1Y: +46.0%
$14.74
+0.24 (+1.66%)
After Hours: $14.65 (-0.09, -0.61%)
Weekly Expected Move ±6.5%
$13
$14
$15
$16
$16
Credit Risk of going bust: lower than 84% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Jade Biosciences, Inc. would be worth roughly what it owes.
Total debt $628K against a stock market value of $922.2M.
Distance to default 10.86 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $314K (short-term plus half of long-term), stock volatility 71.6%; Altman Z'' 16.36. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Jade Biosciences, Inc. would be worth roughly what it owes.
Total debt $628K against a stock market value of $922.2M.
Distance to default 10.86 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $314K (short-term plus half of long-term), stock volatility 71.6%; Altman Z'' 16.36. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$922.2M
52W Range8.36-28
Volume477,455
Avg Volume997,388
Beta1.45
Dividend—
Analyst Ratings
Company Info
CEOTom Frohlich
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-30
Websitejadebiosciences.com
Building 23
Waltham, MA 02453
US
Waltham, MA 02453
US
1 916-322-1700
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Latest News
Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerages
Bank of New York Mellon Corp Invests $1.90 Million in Jade Biosciences, Inc. $JBIO
Analysts Set Jade Biosciences, Inc. (NASDAQ:JBIO) PT at $51.75
HC Wainwright Analysts Increase Earnings Estimates for JBIO
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Eisner Mark | 0 | — | 2026-06-25 | |
| Eisner Mark | A-Award | 47,675 | $21.81 | 2026-06-25 |
| CAIN CHRISTOPHER W. | A-Award | 34,843 | $15.22 | 2026-06-09 |
| DOBMEIER ERIC | A-Award | 34,843 | $15.22 | 2026-06-09 |
| Klein Lawrence Otto | A-Award | 34,843 | $15.22 | 2026-06-09 |